INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $571,933,115 | -19.2% | 10,979,710 | -1.8% | 0.05% | -16.9% |
| Q2 2023 | $708,138,990 | -45.2% | 11,183,496 | -53.2% | 0.06% | 0.0% |
| Q1 2023 | $1,293,117,310 | +103.1% | 23,880,282 | +98.5% | 0.06% | -6.3% |
| Q4 2022 | $636,563,554 | +33.2% | 12,028,790 | +17.1% | 0.06% | +26.0% |
| Q3 2022 | $477,863,000 | -19.0% | 10,269,997 | -0.6% | 0.05% | -15.3% |
| Q2 2022 | $589,811,000 | -12.0% | 10,333,063 | -5.7% | 0.06% | +9.3% |
| Q1 2022 | $670,319,000 | +16.8% | 10,954,710 | -0.1% | 0.05% | +28.6% |
| Q4 2021 | $573,748,000 | +38.9% | 10,961,969 | -1.1% | 0.04% | +27.3% |
| Q3 2021 | $413,099,000 | -16.5% | 11,080,996 | -8.6% | 0.03% | -15.4% |
| Q2 2021 | $494,858,000 | +20.2% | 12,122,894 | -0.1% | 0.04% | +11.4% |
| Q1 2021 | $411,826,000 | +7.7% | 12,137,522 | +0.9% | 0.04% | +2.9% |
| Q4 2020 | $382,349,000 | +25.9% | 12,023,586 | +1.6% | 0.03% | +9.7% |
| Q3 2020 | $303,747,000 | +38.7% | 11,837,342 | +38.8% | 0.03% | +29.2% |
| Q2 2020 | $218,955,000 | +84.0% | 8,529,606 | +10.2% | 0.02% | +50.0% |
| Q1 2020 | $119,005,000 | -45.2% | 7,742,645 | +22.4% | 0.02% | -33.3% |
| Q4 2019 | $216,999,000 | +374.1% | 6,324,655 | +3.2% | 0.02% | +380.0% |
| Q3 2019 | $45,769,000 | -57.4% | 6,126,993 | -25.9% | 0.01% | -61.5% |
| Q2 2019 | $107,347,000 | +6.6% | 8,270,193 | +0.0% | 0.01% | +8.3% |
| Q1 2019 | $100,698,000 | +7.7% | 8,267,510 | +0.7% | 0.01% | -7.7% |
| Q4 2018 | $93,500,000 | -47.5% | 8,208,949 | +0.0% | 0.01% | -35.0% |
| Q3 2018 | $178,075,000 | +22.8% | 8,206,241 | +0.0% | 0.02% | +17.6% |
| Q2 2018 | $144,973,000 | -16.0% | 8,204,457 | +0.0% | 0.02% | -15.0% |
| Q1 2018 | $172,654,000 | +45.6% | 8,202,067 | +0.2% | 0.02% | +42.9% |
| Q4 2017 | $118,543,000 | -5.7% | 8,186,643 | +2.8% | 0.01% | -6.7% |
| Q3 2017 | $125,692,000 | +55.4% | 7,965,260 | +22.3% | 0.02% | +50.0% |
| Q2 2017 | $80,892,000 | -23.6% | 6,513,071 | +0.0% | 0.01% | -23.1% |
| Q1 2017 | $105,813,000 | +8.0% | 6,511,541 | +0.3% | 0.01% | 0.0% |
| Q4 2016 | $97,938,000 | -1.0% | 6,490,236 | +0.0% | 0.01% | 0.0% |
| Q3 2016 | $98,878,000 | -60.7% | 6,488,081 | +0.0% | 0.01% | -61.8% |
| Q2 2016 | $251,744,000 | +39.8% | 6,484,897 | +0.1% | 0.03% | +36.0% |
| Q1 2016 | $180,041,000 | -48.1% | 6,476,306 | +0.4% | 0.02% | -46.8% |
| Q4 2015 | $347,127,000 | +37.9% | 6,453,382 | +2.6% | 0.05% | +30.6% |
| Q3 2015 | $251,758,000 | +50.2% | 6,287,661 | +19.9% | 0.04% | +71.4% |
| Q2 2015 | $167,583,000 | +33.9% | 5,245,175 | +0.1% | 0.02% | +31.2% |
| Q1 2015 | $125,114,000 | +60.8% | 5,239,263 | +18.8% | 0.02% | +60.0% |
| Q4 2014 | $77,829,000 | +28.8% | 4,409,575 | +0.0% | 0.01% | +25.0% |
| Q3 2014 | $60,434,000 | -18.2% | 4,408,008 | +0.5% | 0.01% | -20.0% |
| Q2 2014 | $73,917,000 | -7.2% | 4,384,161 | +0.0% | 0.01% | -9.1% |
| Q1 2014 | $79,690,000 | – | 4,383,412 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |